Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas P Miller

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Transplantation|July 23, 2008
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorderLode J Swinnen, Michael LeBlanc, Thomas M Grogan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2008
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014Daniel O Persky, Joseph M Unger, Catherine M Spier, et al.
Blood|May 10, 2003
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911Oliver W Press, Joseph M Unger, Rita M Braziel, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|February 21, 2003
Gene expression profile of serial samples of transformed B-cell lymphomasSven de Vos, Wolf-Karsten Hofmann, Thomas M Grogan, et al.
Cancer|March 22, 2012
Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare StudyChadi Nabhan, Michelle Byrtek, Michael D Taylor, et al.
Haematologica|January 25, 2012
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy aloneDaniel O Persky, David Dornan, Bryan H Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501William S Velasquez, Danika Lew, Thomas M Grogan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349)Douglas W Blayney, Michael L LeBlanc, Thomas Grogan, et al.
British Journal of Haematology|April 23, 2014
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433Jonathan W Friedberg, Joseph M Unger, W Richard Burack, et al.
Blood|November 15, 2014
Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313Daniel O Persky, Thomas P Miller, Joseph M Unger, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Transplantation|July 23, 2008
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorderLode J Swinnen, Michael LeBlanc, Thomas M Grogan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2008
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014Daniel O Persky, Joseph M Unger, Catherine M Spier, et al.
Blood|May 10, 2003
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911Oliver W Press, Joseph M Unger, Rita M Braziel, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|February 21, 2003
Gene expression profile of serial samples of transformed B-cell lymphomasSven de Vos, Wolf-Karsten Hofmann, Thomas M Grogan, et al.
Cancer|March 22, 2012
Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare StudyChadi Nabhan, Michelle Byrtek, Michael D Taylor, et al.
Haematologica|January 25, 2012
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy aloneDaniel O Persky, David Dornan, Bryan H Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501William S Velasquez, Danika Lew, Thomas M Grogan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349)Douglas W Blayney, Michael L LeBlanc, Thomas Grogan, et al.
British Journal of Haematology|April 23, 2014
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433Jonathan W Friedberg, Joseph M Unger, W Richard Burack, et al.
Blood|November 15, 2014
Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313Daniel O Persky, Thomas P Miller, Joseph M Unger, et al.
Pageof 7